218 related articles for article (PubMed ID: 32684074)
1. Advances in steroid sparing medical management of active thyroid eye disease.
Liou VD; Yoon MK
Semin Ophthalmol; 2020 May; 35(4):216-223. PubMed ID: 32684074
[TBL] [Abstract][Full Text] [Related]
2. Adalimumab as steroid-sparing treatment of inflammatory-stage thyroid eye disease.
Ayabe R; Rootman DB; Hwang CJ; Ben-Artzi A; Goldberg R
Ophthalmic Plast Reconstr Surg; 2014; 30(5):415-9. PubMed ID: 24978425
[TBL] [Abstract][Full Text] [Related]
3. Teprotumumab for the treatment of thyroid eye disease.
Fallahi P; Ragusa F; Paparo SR; Elia G; Balestri E; Mazzi V; Patrizio A; Botrini C; Benvenga S; Ferrari SM; Antonelli A
Expert Opin Biol Ther; 2023 Feb; 23(2):123-131. PubMed ID: 36695097
[TBL] [Abstract][Full Text] [Related]
4. Advances in the management of thyroid eye diseases: An overview.
Kumari R; Chandra Saha B
Int Ophthalmol; 2018 Oct; 38(5):2247-2255. PubMed ID: 28822031
[TBL] [Abstract][Full Text] [Related]
5. Acute thyroid eye disease (TED): principles of medical and surgical management.
Verity DH; Rose GE
Eye (Lond); 2013 Mar; 27(3):308-19. PubMed ID: 23412559
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Immunosuppressive Agents for Thyroid Eye Disease.
Strianese D
Ophthalmic Plast Reconstr Surg; 2018; 34(4S Suppl 1):S56-S59. PubMed ID: 29923966
[TBL] [Abstract][Full Text] [Related]
7. Understanding Pathogenesis Intersects With Effective Treatment for Thyroid Eye Disease.
Smith TJ
J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S13-S26. PubMed ID: 36346686
[TBL] [Abstract][Full Text] [Related]
8. Thyroid eye disease: current and potential medical management.
Pouso-Diz JM; Abalo-Lojo JM; Gonzalez F
Int Ophthalmol; 2020 Apr; 40(4):1035-1048. PubMed ID: 31919775
[TBL] [Abstract][Full Text] [Related]
9. Tear inflammatory cytokines and ocular surface changes in patients with active thyroid eye disease treated with high-dose intravenous glucocorticoids.
Xu N; Cui Y; Fu D; Sun F
J Endocrinol Invest; 2020 Jul; 43(7):901-910. PubMed ID: 31927748
[TBL] [Abstract][Full Text] [Related]
10. Thinking inside the box: Current insights into targeting orbital tissue remodeling and inflammation in thyroid eye disease.
Gupta V; Hammond CL; Roztocil E; Gonzalez MO; Feldon SE; Woeller CF
Surv Ophthalmol; 2022; 67(3):858-874. PubMed ID: 34487739
[TBL] [Abstract][Full Text] [Related]
11. A Review of Novel Medical Treatments for Thyroid Eye Disease.
Park JW; Yoon JS
Korean J Ophthalmol; 2024 Jun; 38(3):249-259. PubMed ID: 38773958
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of teprotumumab therapy in patients with long-duration thyroid eye disease.
Subramanian PS; Cho RI; Kahana A
Curr Opin Ophthalmol; 2023 Nov; 34(6):487-492. PubMed ID: 37610428
[TBL] [Abstract][Full Text] [Related]
13. Teprotumumab reduces extraocular muscle and orbital fat volume in thyroid eye disease.
Jain AP; Gellada N; Ugradar S; Kumar A; Kahaly G; Douglas R
Br J Ophthalmol; 2022 Feb; 106(2):165-171. PubMed ID: 33172865
[TBL] [Abstract][Full Text] [Related]
14. Change in lacrimal gland volume and aqueous tear production following treatment with teprotumumab.
Ugradar S; Zimmerman E; Parunakian E; Kang J; Cockerham K; Douglas RS
Clin Exp Ophthalmol; 2023; 51(4):339-348. PubMed ID: 36723406
[TBL] [Abstract][Full Text] [Related]
15. Teprotumumab (Tepezza) for Thyroid Eye Disease.
Couch SM
Mo Med; 2022; 119(1):36-41. PubMed ID: 36033157
[TBL] [Abstract][Full Text] [Related]
16. Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease.
Kossler AL; Douglas R; Dosiou C
J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S36-S46. PubMed ID: 36346685
[TBL] [Abstract][Full Text] [Related]
17. A Paradigm Shift in the Management of Thyroid Eye Disease How Teprotumumab Has Changed the Therapeutic Interface.
Ugradar S; Kossler AL; Douglas R; Cockerham K
J Neuroophthalmol; 2022 Mar; 42(1):26-34. PubMed ID: 35500236
[TBL] [Abstract][Full Text] [Related]
18. Medical treatment in thyroid eye disease in 2020.
Khong JJ; McNab A
Br J Ophthalmol; 2021 Mar; 105(3):299-305. PubMed ID: 32447327
[TBL] [Abstract][Full Text] [Related]
19. Teprotumumab: Interpreting the Clinical Trials in the Context of Thyroid Eye Disease Pathogenesis and Current Therapies.
Winn BJ; Kersten RC
Ophthalmology; 2021 Nov; 128(11):1627-1651. PubMed ID: 33930408
[TBL] [Abstract][Full Text] [Related]
20. Early use of steroid-sparing agents in the inactivation of moderate-to-severe active thyroid eye disease: a step-down approach.
Sipkova Z; Insull EA; David J; Turner HE; Keren S; Norris JH
Clin Endocrinol (Oxf); 2018 Dec; 89(6):834-839. PubMed ID: 30103255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
